Literature DB >> 26390915

Practical Synthesis, Antidepressant, and Anticonvulsant Activity of 3-Phenyliminoindolin-2-one Derivatives.

Jian-Yin Ma1, Ying-Chun Quan2, Hong-Guo Jin3, Xing-Hua Zhen1, Xue-Wu Zhang2, Li-Ping Guan1.   

Abstract

Herein, a series of 3-phenyliminoindolin-2-one derivatives were designed, synthesized, and screened for their antidepressant and anticonvulsant activities. The IR spectra of the compounds afforded NH stretching (3340-3346 cm(-1)) bands and C=O stretching (1731-1746 cm(-1)). In the (1)H-NMR spectra of the compounds, N-H protons of indoline ring were observed at 10.65-10.89 ppm generally as broad bands, and (13)C-NMR spectra of the compounds C=O were seen at 161.72-169.27 ppm. Interestingly, compounds 3o, 3p and 3r significantly shortened immobility time in the The forced swimming test (FST) and The tail suspension test (TST) at 50 mg/kg dose levels. In addition, compound 3r exhibited higher levels of efficacy than the reference standard fluoxetine but had no effect on locomotor activity in the open-field test. Compound 3r significantly increased serotonin and norepinephrine and the metabolite 5-hydroxyindoleacetic acid in mouse brain, suggesting that the effects of compound 3r may be mediated through these neurotransmitters. In the seizure screen, 15 compounds showed some degree against PTZ-induced seizure at a dose of 100 mg/kg, and the tested compounds did not show any neurotoxicity at a dose of 300 mg/kg in the rotarod test.
© 2015 John Wiley & Sons A/S.

Entities:  

Keywords:  antidepressant; neuro-transmitters; pentylenetetrazole; phenyliminoindolin-2-one

Mesh:

Substances:

Year:  2015        PMID: 26390915     DOI: 10.1111/cbdd.12668

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  1 in total

1.  Synthesis of 1,3-diaryl-spiro[azetidine-2,3'-indoline]-2',4-diones via the Staudinger reaction: cis- or trans-diastereoselectivity with different addition modes.

Authors:  Vadim Filatov; Maksim Kukushkin; Juliana Kuznetsova; Dmitry Skvortsov; Viktor Tafeenko; Nikolay Zyk; Alexander Majouga; Elena Beloglazkina
Journal:  RSC Adv       Date:  2020-04-06       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.